Clinical Trials Browser

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT05126433 2025-02-28

JAZZ EMERGE201

Phase 2 Terminated

47 enrolled 16 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Phase 3 Recruiting

180 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04638491 2024-06-10

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

Phase 1 Completed

32 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Phase 2 Completed

345 enrolled 34 charts 2 FDA

Other solid neoplasm

Advanced Solid Tumors

NCT02566993 2021-10-28

ATLANTIS

Phase 3 Completed

613 enrolled 46 charts

Thoracic

Small Cell Lung Carcinoma

NCT04291937 2020-06-19

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Approved for marketing

Thoracic

Small Cell Lung Carcinoma

NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Phase 1 Completed

69 enrolled 17 charts

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02421588 2020-04-03

CORAIL

Phase 3 Completed

442 enrolled 33 charts

Gynecologic

Ovarian Neoplasms

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Phase 1 Completed

122 enrolled 19 charts

EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02451007 2019-11-19

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

Phase 2 Completed

39 enrolled 11 charts

Other solid neoplasm

Solid Tumors

NCT01951157 2019-09-24

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Completed

69 enrolled 28 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Phase 1 Completed

41 enrolled

Tumor-Agnostic

Neoplasms

NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Phase 1 Completed

81 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01405391 2016-01-15

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

Phase 1 Completed

42 enrolled

GastrointestinalOther solid neoplasm

Major Advanced Solid Tumors Other Than Colorectal

NCT01314599 2015-11-05

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Phase 1 Completed

45 enrolled

Other hematologic neoplasm

Leukemia

NCT00877474 2015-11-04

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Phase 1 Completed

30 enrolled

Other solid neoplasm

ADVANCED SOLID TUMORS

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

Phase 1 Completed

47 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

SEZanne

SaLuDo

IMforte

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

IDeate-Lung02

SCLC

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

DeLLphi-304

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

JAZZ EMERGE201

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

ATLANTIS

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

CORAIL

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors